Our team has worked especially hard to anticipate our customers' needs for quality and speed. Drug development technology continues to advance rapidly. The business improvement was primarily because of rising sales of BAS's Culex automated blood sampling instruments, and from significant growth in bioanalytical and preclinical contract research services. We have enabled and embraced change. More changes are coming.
Productivity continues to improve.
That is good news for shareholders and patients. Taglich Brothers thinks BAS management will use the Culex device as a bridge to expand its services segment, he said. Terms of Service Contact us with comments, concerns, or questions. Inc. A Gannett Site. Use of this site signifies your agreement to the Terms of Service .